The Ledger

31.5 million dollars: that is what a Sunnyvale startup just raised to build a single procedure that images and treats the prostate, with one of the world’s largest device makers as a new backer. MaxQ Medical, a Sunnyvale, California health technology company, announced August 20, 2026 it raised $31.5 million in Series A financing led by Atlantic Blue Ventures and S3 Ventures, with Olympus Innovation Ventures, the venture arm of Japanese medical device maker Olympus Corporation, and existing investor Hillside Capital also participating. MaxQ is developing an investigational platform that combines ultrasound imaging with tissue-selective therapy, letting urologists visualize and treat targeted prostate tissue through the urethra in a single procedure; the company says the capital will fund its ongoing clinical program and organizational growth as the device moves toward later-stage development, with an eye toward applying the same core technology across other prostate care indications. Confidence: High on the deal terms and investor list, which come directly from the company’s own release. Medium on the device’s eventual clinical and commercial prospects, which remain unproven; MaxQ has not disclosed a specific regulatory pathway or timeline. Source: MaxQ Medical Raises $31.5 Million Series A, Backed by Olympus, to Advance its Prostate Care Platform, PR Newswire.

30 million dollars: that is how much a women’s health device maker has now raised in a Series C round that exists because its comeback product is finally selling. Channel Medsystems, a privately held medical technology company focused on heavy menstrual bleeding and dysmenorrhea, announced August 20, 2026 that its Series C financing has reached $30 million, led by InnovaHealth Partners. The company says the new capital follows the successful commercial relaunch of Cerene, its cryotherapy platform that uses freezing rather than heat to treat heavy periods as an alternative to surgical endometrial ablation, and will fund expansion of its commercial organization, physician and patient education, and broader access to the device. Confidence: High on the funding figure and lead investor, drawn directly from the company’s own release. Low on Cerene’s specific sales trajectory, which the company did not quantify. Source: Channel Medsystems Series C, led by InnovaHealth Partners, LP, Reaches $30 Million as the Company Accelerates Commercial Expansion of Cerene, GlobeNewswire via BioSpace.

14: that is how many years a point-of-care advertising platform spent under one private equity owner before another one bought control of it, on terms neither side will disclose. Providence Equity Partners, a global private equity firm, agreed to acquire a majority stake in CheckedUp, a specialty point-of-care education and engagement platform that delivers clinically aligned content plus pharmaceutical and life-sciences advertising through waiting-room televisions and exam-room touchscreens, the companies announced August 18, 2026. CheckedUp, founded in 2012, was previously controlled by Rockbridge Growth Equity, the Detroit-based private equity firm co-founded by Dan Gilbert, which is exiting its investment; Varsity Healthcare Partners is joining as a minority investor alongside Providence Equity. Neither the purchase price nor other financial terms were disclosed; the transaction is expected to close in the third quarter of 2026. Confidence: High on the deal structure and parties, which come directly from both companies’ own releases. Low on valuation, which neither side disclosed. Sources: Providence Equity Partners to Acquire Majority Stake in CheckedUp, Businesswire, Rockbridge Growth Equity Announces Sale of CheckedUp to Providence Equity Partners, PR Newswire.

2022: that is the year a staffing firm was founded that a much larger rival just bought outright to fix its own shortage of anesthesia providers. CHG Healthcare, a Salt Lake City-based healthcare staffing company, announced August 11, 2026 it has acquired KREWE Anesthesia, a staffing firm specializing in certified registered nurse anesthetists (CRNAs) that was founded in 2022. KREWE provides locum tenens staffing, workforce management and customized coverage solutions for CRNAs, one of the most acute gaps in healthcare workforce management as hospitals and surgery centers compete for a limited supply of anesthesia providers; CHG did not disclose the purchase price. Confidence: High on the transaction’s existence and structure, drawn directly from CHG’s own release. The undisclosed price means the deal’s scale relative to CHG’s existing staffing business cannot be independently assessed this run. Source: CHG Healthcare Acquires KREWE Anesthesia To Expand CRNA Staffing Capabilities, Meeting Rising Client Needs, Businesswire.

THE DEAL SHEET

Target	Acquirer/Investor	Vertical	Value	Source
MaxQ Medical	Atlantic Blue Ventures and S3 Ventures (led), Olympus Innovation Ventures, Hillside Capital	Medtech, urology devices	$31.5 million Series A; announced August 20, 2026	MaxQ Medical Raises $31.5 Million Series A, PR Newswire
Channel Medsystems	InnovaHealth Partners (led)	Medtech, women’s health devices	Series C reaches $30 million; announced August 20, 2026	Channel Medsystems Series C Reaches $30 Million, GlobeNewswire via BioSpace
CheckedUp	Providence Equity Partners (majority), Varsity Healthcare Partners (minority); seller Rockbridge Growth Equity	Point-of-care health engagement and advertising platform	Undisclosed; announced August 18, 2026, expected to close Q3 2026	Providence Equity Partners to Acquire Majority Stake in CheckedUp, Businesswire
KREWE Anesthesia	CHG Healthcare	Healthcare staffing, CRNA and anesthesia	Undisclosed; announced August 11, 2026	CHG Healthcare Acquires KREWE Anesthesia, Businesswire

This run’s scan of PE Hub, Axios Pro Rata, FTC and DOJ merger actions and state transaction-review dockets over the last 24 to 48 hours found the four transactions above; no new FTC or DOJ healthcare antitrust actions were spotted in this window.